Title: Cabergoline and quinagolide therapy for prolactinomas
Abstract: Clinical EndocrinologyVolume 53, Issue 5 p. 549-550 Cabergoline and quinagolide therapy for prolactinomas J. Webster, J. Webster Northern General Hospital, Sheffield, UKSearch for more papers by this author J. Webster, J. Webster Northern General Hospital, Sheffield, UKSearch for more papers by this author First published: 09 October 2008 https://doi.org/10.1046/j.1365-2265.2000.01147.xCitations: 9 Dr Simone BjerregårdSneppen Department of Endocrinology PE 2131, The National University Hospital, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. Fax: +45 35 45 22 40 Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Bibliography 1 Bevan, J.S., Webster, J., Burke, C.W., Scanlon, M.F. (1992) Dopamine agonists and pituitary tumor shrinkage. Endocrine Reviews, 13, 220 240. 2 Ciccarelli, E., Grottoli, S., Razzore, P., Gaia, D., Bertagna, A., Cirillo, S., Cammarota, T., Cammanni, M, Camanni, F. (1997) Long-term treatment with cabergoline, a new long-lasting ergoline derivative, in idiopathic or tumorous hyperprolactinemia and outcome of drug-induced pregnancy. Journal of Endocrinological Investigation, 20, 547 551. 3 Di Sarno, A., Landi, M.L., Marzullo, P., Di Somma, C., Pivonello, R., Cerbone, G., Lombardi, G., Colao, A. (2000) The effect of quinagolide and cabergoline, two selective dopamine receptor type-2 agonists, in the treatment of prolactinomas. Clinical Endocrinology, 53, 53 60.DOI: 10.1046/j.1365-2265.2000.01016.x 4 Giusti, M., Porcella, E., Carraro, A., Cuttica, M., Valenti, S., Giordano, G. (1994) A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinaemic patients. Journal of Endocrinological Investigation, 17, 51 57. 5 Van Der Heijden, P.F.M., De Wit, W., Brownell, J., Schoemaker, J., Rolland, R. (1991) CV205–502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia. European Journal of Obstetrics, Gynecology and Reproductive Biology, 40, 111 118. 6 Homburg, R., West, C., Brownell, J., Jacobs, H.S. (1990) A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205–502, with bromocriptine in women with hyperprolactinaemia. Clinical Endocrinology, 32, 565 571. 7 Muratori, M., Arosio, M., Gambino, G., Romano, C., Biella, O., Faglia, G. (1997) Use of cabergoline in the long term treatment of hyperprolactinemic and acromegalic patients. Journal of Endocrinological Investigation, 20, 537 546. 8 Verhelst, J.A., Froud, A.L., Touzel, R., Wass, J.A., Besser, G.M., Grossman, A.B. (1991) Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinaemia: a double blind study. Acta Endocrinologica, 125, 385 391. 9 Webster, J., Piscitelli, G., Polli, A., Ferrari, C.I., Ismail, I., Scanlon, M.F. (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinaemic amenorrhoea. New England Journal of Medicine, 331, 904 909. Citing Literature Volume53, Issue5November 2000Pages 549-550 ReferencesRelatedInformation
Publication Year: 2000
Publication Date: 2000-11-17
Language: en
Type: letter
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 14
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot